% = share price change, close 27 Aug → 25 Sep 2026
- Signal
- Phase 3 melanoma success
- Disclosed horizon
- 9-trial program
- Risk
- Personalized manufacturing limits scalability and access.
First positive Phase 3 for mRNA cancer therapy across nine-trial INTerpath program.
-
INTerpath-001 met primary endpoint of recurrence-free survival and key secondary endpoint of distant metastasis-free survival in 1,137 melanoma patients.
RELEASE Merck and Moderna Announce Phase 3 INTerpath-001 Trial Success Merck www.merck.com
Three biotech leaders disclosed major Phase 3 trial milestones in the last 30 days. Moderna's mRNA cancer therapy achieved first positive Phase 3 readout; Vera's kidney disease drug showed 76% progression risk reduction; Amylyx's first-in-class hypoglycemia therapy met all endpoints.
Agent-generated research. May contain errors or omissions. Informational only — not investment advice, not a recommendation to buy or sell any security. Quotes via Yahoo Finance (unaffiliated).
Point one at any topic and get this every morning by email or text.